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Objective and Summary Background Data
Because of the shortage of available donor organs, death
rates from liver failure remain high. Therefore, several tempo-
rary liver-assisting therapies have been developed. This article
reviews various approaches to temporary liver support as well
as immunologic and metabolic developments toward a solu-
tion for this problem.
Methods
A literature review was performed using Medline and addi-
tional library searches to obtain further references. Only arti-
cles with a well-defined aim of study and methodology and a
clear description of the outcome of the experiments were in-
cluded.
Conclusions
Renewed interest has developed in old and new methods for
an extracorporeal approach to the treatment of acute liver
failure. Although temporary clinical improvement has been
established, further research is needed to achieve a success-
ful long-term clinical outcome. New developments in the field
of genetic modification and tissue engineering await clinical
application in the near future.
Because of the life-threatening complications of acute
liver failure (ALF), 75% of patients die within a few days of
onset. At present there is no satisfactory treatment for ALF
except liver transplantation. Although liver transplantation
is successful, with 5-year survival rates ranging from 70%
to 80%, there is a shortage of available donor organs. It is
estimated that in the United States only 20% of the patients
with ALF receive a transplant; 80% die while on the waiting
list.1 The clinical need for an alternative is twofold: first, to
bridge the gap until liver transplantation in case of irrevers-
ible damage, and second, to gain time for regeneration of
the damaged liver.
Various liver-assisting therapies have been introduced
since the early 1960s, including plasmapheresis, hemodilu-
tion, and cross-circulation, but none of them led to a sig-
nificant clinical improvement. At the same time, extracor-
poreal whole liver perfusion was developed, with promising
results. This method was abandoned in the early 1970s,
however, because of the successful development of ortho-
topic liver transplantation and awareness of the possible
immunologic implications. At present, the consensus is that
the multiple and complex functions of the liver can be
replaced only by using the biologic substrate (i.e., hepato-
cytes), whether in a whole liver or in combination with
artificial material. This has led to increasing interest in the
development of a bioartificial liver along with extracorpo-
real liver perfusion.
In addition to the worldwide shortage of available donor
organs, new developments have made it worthwhile to
pursue these solutions to the problem of ALF. The disad-
vantages and long-term effects of liver transplantation have
become clear: a major and costly surgical procedure and
lifelong immunosuppressive therapy. Further, the possibil-
ity of genetically modifying donor animals creates a unique
opportunity to overcome potential immunologic barriers
between species. In this review, we will assess the various
approaches to a temporary solution for ALF; their short-
comings will be discussed and directions for future research
suggested.
EARLY LIVER-SUPPORT THERAPIES
Acute or fulminant hepatic failure, usually induced by
chemical or viral hepatitis, is highly lethal, with a death rate
of more than 75% as a result of life-threatening complica-
tions such as portal hypertension, variceal bleeding, ascites,
and hepatic encephalopathy. While the patient is waiting for
possible liver transplantation, current treatment consists of
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intensive clinical support: fluid and hemodynamic support,
correction of electrolyte and acid–base abnormalities, respi-
ratory assistance, and treatment of cerebral edema. In the
past, it was thought that encephalopathy and cerebral edema
were caused mainly by dialyzable toxins such as ammonia,
false neurotransmitters, phenols, aromatic amino acids, and
other substances with a molecular weight of less than
5,0002; early liver-support systems focused on blood detox-
ification. A kidney dialysis machine was used to remove
blood ammonia, but this did not result in clinical improve-
ment.3 Because most of these toxins were thought to be
protein-bound and traditional hemodialysis used cellulose
membranes impervious to large molecules, polyacrylonitrile
membranes were introduced that allowed passage of mole-
cules up to a molecular weight of 15 kDa. Table 1 summa-
rizes the results of the early liver-support therapies intro-
duced in the 1950s and 1960s. In two groups treated with
hemodialysis,4,5 temporary improvement in mental status
and duration of survival occurred in more than half of the
patients, suggesting at least partially effective removal of
neurotoxins.
Hemofiltration has seen only limited application because
of its major complication of thrombocytopenia, leading to
bleeding in patients with an already compromised clotting
system.6,7 Exchange transfusion showed initial improve-
ment in neurologic status in several trials, but no effect on
the death rate was found.8–12 With the less laborious tech-
nique of plasma exchange or plasmapheresis,13–15 signifi-
cant improvements in neurologic status and biochemical
profiles and decreased bleeding episodes were demonstrat-
ed; control of the hemorrhagic diathesis was achieved
through the addition of coagulation factors. With this
method, a better overall survival rate was achieved (34% vs.
14% in the nontreated group); however, this was a nonran-
domized study, and the groups were not controlled for cause
or severity of the underlying disease.16
In hemoperfusion or plasma perfusion, the blood or
plasma of a patient with ALF is perfused through a column
containing activated charcoal or anion exchange resins. The
latter caused no significant improvement, mainly because of
early saturation of the resins and nonselective binding of the
cations removed.17,18 After resolving the problems of plate-
let loss and hypotensive reactions by coating the columns
and administering prostacyclin as a protective agent for the
platelets,2,19 charcoal hemoperfusion yielded encouraging
survival rates among patients with ALF.20–23 However,
none of these studies included a proper control group de-
fined by both the cause of the hepatic failure and the stage
of disease. Thus, the effect of coated charcoal perfusion
cannot be estimated conclusively. This technique is still in
use because of the possible beneficial effect in combination
therapies, where it is supposed to protect the adjacent liver-
support therapy from toxic substances.
The detoxifying function of the above-mentioned tech-
niques may in itself not be enough to improve the survival
of patients with ALF. It remains to be determined whether
these techniques, in combination with other liver-support
therapies, will play a role in the future.
BIOARTIFICIAL LIVER
The limited success of detoxifying liver-support therapies
and improved techniques for culturing isolated hepatocytes
that express high levels of differentiated liver function in
vitro have led to the development of the hybrid or bioarti-
ficial liver (BAL). These systems consist of biologic com-
ponents (freshly isolated pig hepatocytes or human hepato-
blastoma cell lines) in a synthetic framework. Isolated
hepatocytes have been used in two ways, extracorporeal
hepatocyte bioreactors and implantable hepatocyte systems;
the latter is beyond the scope of this paper. In the extracor-
poreal bioreactors, the blood or plasma of the patient with
ALF comes in contact with the cultured hepatocytes through
an ex vivo perfusion system, as in the hemodialysis system
for patients with renal insufficiency.
To create an artificial system containing viable hepato-
cytes, the procedure of culturing hepatocytes while main-
taining their liver-specific function had to be improved.
Culturing hepatocytes in suspension or in plastic tissue
culture dishes causes the cells to lose their function within
24 hours and leads to cell death within days.24,25 Two
solutions to this problem are being investigated: the use of
transformed cells or cell lines, and optimization of the
culture system for primary isolated hepatocytes. Another
problem is how to expand the cell cultures to obtain suffi-
cient quantities of hepatocytes in a relatively small volume
Table 1. PATIENTS TREATED WITH EARLY LIVER-SUPPORT THERAPIES
Support System No. of Patients
Neurologic Improvement
SurvivalYes No Unknown
Hemodialysis4,5 65 33 17 15 17 (26%)
Hemofiltration6,7 15 10 5 0 8 (53%)
Exchange transfusion8–12 48 24 16 8 9 (19%)
Plasma exchange13–15 32 15 17 0 7 (22%)
Resin hemoperfusion17,18 9 5 4 0 0 (0%)
Charcoal perfusion20–23 278 73 101 104 116 (42%)
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to replace completely the function of a human liver.26
During the past 10 years, the development of clinically
applicable BAL systems has focused on the volume of
hepatocytes necessary to replace temporarily the liver func-
tion of the patient with ALF.
Hepatocytes in Suspension Cultures or
Encapsulated in Hydrogels
Hepatocytes were first used in a liver support system in a
clinical setting in 1987 by Matsamura et al (Table 2).27
Hepatocytes in a suspension culture were separated from the
patient’s blood by a cellulose acetate dialysis membrane. In
this single patient, some clinical improvement was found.
Because in vitro studies showed that hepatocytes function
better when attached to a substrate, another attempt to
establish a suspension system was made by Margulis et al,28
who seeded liver cells on Biosilon microcarriers. They
demonstrated improved survival rates in the treated group
(63%) versus the group that received standard medical
treatment (41%). However, randomization for the stage of
liver disease was not performed in the different groups, and
no follow-up cases have been reported. Further in vitro
studies demonstrated poorly preserved hepatocyte function
after several hours of application.28,29
A rotating-disk type of artificial liver system, with hepa-
tocytes trapped in a calcium alginate hydrogel, showed
ammonia metabolism and urea synthesis in in vitro studies
and subsequently significant removal of ammonia in an ex
vivo animal study.30 Drawbacks of this system are the
tendency of the gel phase to dissolve during hemoperfusion,
with consequent loss of viability of the entrapped hepato-
cytes. This is why it was never applied in a clinical setting.
Multiplated Hepatocyte Monolayers
The system, which best resembles an in vitro culture of
hepatocytes, was designed by Uchino et al in 1988.31 Hepa-
tocytes were isolated from a canine liver and cultured on
collagen-coated borosilicated glass plates in a monolayer.
Stacking 200 plates in a transparent acryl resin module
yielded about 80 g of hepatocytes, or one third of a canine
liver, with stable function of the hepatocytes for 14 days.
When this device was used to treat anhepatic dogs, clear-
ance of ammonia was demonstrated in the treated group (vs.
the groups receiving no treatment or plasma perfusion) and
led to a significant increase in overall survival (55 vs. 24
hours). The same system has been used in in vitro studies of
pig hepatocytes, which were perfused with plasma from
patients with hepatic failure,32 and in the testing of in vitro
hepatocyte culture techniques such as coculture and colla-
gen-sandwich culture.33,34 These studies yielded the same
encouraging results in vitro, but thus far no report of a
clinical application has been published.
Hollow Fiber Systems
Most devices used to create a BAL consist of a bundle of
small-diameter tubes, made of compatible cellulose acetate,
enclosed in a rigid polycarbonate module (Fig. 1). This
hollow fiber system has two compartments (intraluminal
within the fibers and extraluminal outside the fibers) within
the rigid housing; they communicate through the pores in
the fiber walls. Because most of the waste molecules and
bilirubin are bound to albumin (molecular weight 65–70
kDa), the pore size chosen is usually a nominal molecular
weight cutoff of 100 kDa; this excludes most complement
factors and immunoglobins.35
Intraluminal Gel Entrapment of Porcine
Hepatocytes
Prolonged viability and functioning of the hepatocytes
are difficult to maintain at a high seeding density in an
artificial liver. The viability and liver-specific functioning of
hepatocytes are maintained by meeting several conditions,
such as culturing on specific extracellular matrices,36,37
using a hormone-enriched culture medium,38,39 and ensur-
ing three-dimensional orientation of the cultured hepato-
cytes.37 Gel entrapment of hepatocytes allows most of the
above. In these bioreactors, the primary isolated hepatocytes
are inoculated into a collagen suspension in the intraluminal
fiber space. The solution rapidly gels, resulting in hepato-
cytes entrapped in a three-dimensional matrix in the hollow
fibers. The hepatocyte/collagen gel subsequently contracts
to less than 50% of the original cross-section, resulting in
three compartments: the contracted gel containing the hepa-
tocytes, the rest of the intraluminal hollow fiber space, and
Table 2. PATIENTS TREATED WITH ARTIFICIAL LIVER DEVICES
Support System No. of Patients
Neurologic Improvement
Survival OLTYes No Unknown
Suspension culture27,28 60 60 0 38 (63%) 0
Extracorporeal liver-assist device45,46 23 18 5 14 (61%) 3
Bioartificial liver52 31 30 1 22 (71%) 21
OLT, orthotopic liver transplantation.
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the extraluminal space within the rigid housing. Hepatocyte
culture medium is perfused through the intraluminal space
to keep the hepatocytes viable and functional when another
medium (in the future, the patient’s blood) is perfused
through the extraluminal space. Proper functioning of this
bioreactor has been demonstrated for 5 consecutive days in
vitro, as measured by albumin synthesis, ureagenesis, and
oxygen consumption.40 In an animal model of hepatic fail-
ure in small dogs (,30 kg), improved hemodynamic sta-
bility, delayed or absent hepatic encephalopathy, and im-
proved survival were shown.41 Unfortunately, this concept
yields only 0.5 to 1.0 g cells per bioreactor,42 which is not
enough to treat humans. Although further characterization
studies are being performed,43 the distance required for
nutrients and exchangeable medium of the intraluminal
gel-entrapped hepatocytes is not known, whereas the whole
process of exchanging nutrients and toxic substances is
dependent on passive diffusion through this gel.
Extracorporeal Liver-Assist Device
The C3A cell line is a highly differentiated, stable, and
viral-free human cell line that performs a range of metabolic
functions comparable to those of the normal liver. It has
been shown to maintain viability and function for 4 to 8
months when seeded in a hollow fiber cartridge at high
seeding density. In this concept, approximately 10 g C3A
cells is injected into the extraluminal space; the cells grow
to confluence in 3 to 4 weeks and do not outgrow their
culture space. Maturity is determined by glucose use and
albumin production. It is thought that approximately 200 g
C3A cells (2 3 1011 hepatocytes) is seeded in the bioreactor
at confluence.44 Animal studies of dogs with acetamino-
phen-induced hepatic failure showed a significant biochem-
ical improvement and improved survival. However, al-
though the fibers have a nominal molecular weight cutoff of
70 kDa, human proteins such as human transferrin (molec-
ular weight 90 kDa) and a1-antitrypsin were detected in dog
serum, suggesting the transfer of human cell line material to
the (canine) patient.44 Initial experience was encouraging:
11 patients were treated with the extracorporeal device and
no short-term safety problems were observed; 10 patients
showed biochemical improvement and 6 patients survived
(see Table 2).45 In a second study, a pilot controlled trial,
Ellis et al46 reported good survival for the treated group
(78%), but surprisingly also for the group receiving con-
ventional treatment (75%). The authors attribute the out-
come of this trial to their choice of a group of patients with
ALF at an earlier stage of the clinical course, when accurate
predictors of prognosis are lacking. Further clinical studies
will have to be performed to be able to justify the use of this
system for patients with liver failure. More importantly, the
long-term effects of leakage of human cell line material into
the circulation of future patients, as previously shown,47
need to be assessed before the safety of this system can be
established conclusively.
Bioartificial Liver
Because hepatocytes are known to be anchorage-depen-
dent for prolonged viability and functioning, and to increase
the effective surface area for hepatocytes in the hollow fiber
cartridge, Demetriou et al48 used collagen-coated microcar-
riers for their BAL. After isolation of primary pig hepato-
cytes, the cells are incubated overnight with collagen-coated
dextran microcarriers for attachment, and the microcarrier-
attached hepatocytes are inoculated into the extraluminal
compartment of the hollow fiber system. In vitro and in vivo
studies showed hepatocyte viability and functioning on mi-
crocarriers by conjugation of bilirubin, uptake of 99mTc-
DESIDA, and synthesis of liver-specific proteins (e.g., al-
bumin) after implantation in albumin-deficient rats for 6
days. Moreover, similar functioning was measured after 2
weeks of storage of the microcarrier-attached hepatocytes at
280°C, suggesting that this part of the bioreactor can be
prepared in advance. In vitro mass transfer studies were
performed to determine the optimal operating parameters
for a hollow fiber cartridge serving as a BAL. These studies
Figure 1. Liver support device. After plasmaphere-
sis, plasma circulates through a hollow fiber system in
which isolated pig hepatocytes are cultured in the
extracapillary space.
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demonstrated that cells attached to the microcarriers do not
bind to the fibers, thereby allowing free convection of
plasma/perfusion medium with an optimal cross-fiber pres-
sure drop at high-flow recirculation of plasma.49 Significant
metabolic support was shown when cryopreserved micro-
carrier-attached pig hepatocytes were used in the BAL to
treat dogs with acute liver failure continuously for 6 hours,
introducing plasmapheresis to avoid hemolysis and platelet
depletion in the perfusion system. The viability of the cells
after 6 hours of both allogeneic and xenogeneic perfusion
was 90%. Unfortunately, survival was not one of the end-
points of this study.50 A charcoal column was added to the
extracorporeal perfusion system before perfusion through
the BAL because it was assumed that this would protect the
porcine hepatocytes from the toxic hepatic failure plasma.51
This system, including plasmapheresis, charcoal column,
and cryopreserved primary isolated microcarrier-attached
pig hepatocytes (approximately 4–6 3 109) inoculated into
the extraluminal space of a hollow fiber cartridge, was used
for the first time to treat a patient in 1993, leading to a phase
I clinical trial with 31 patients (see Table 2). Eighteen
patients with fulminant hepatic failure, 3 patients with pri-
mary nonfunction after liver transplantation, and 10 patients
with acute exacerbation of chronic liver disease were treated
successfully, as indicated by significant neurologic im-
provement, decreased intracranial pressure, decreased
plasma ammonia levels, and improvement of other bio-
chemical parameters. Liver transplantation followed in 21
of the 31 patients; the other 8 patients were not eligible for
transplantation.52
Although this system gave promising results and a phase
II/III clinical trial is being prepared to determine efficacy,
further studies are needed to establish the immunologic
consequences of perfusing human plasma through a device
containing pig hepatocytes. In addition, the possible transfer
of viral material from the bioreactor to the host must be
monitored in detail.
Also, the long-term stable culture of human hepatocytes
must be explored. Recent studies have shown normal pro-
liferation of human blastocyst-derived, pluripotential em-
bryonic stem cell lines, which differentiate into derivatives
of all three embryonic germ layers.53 These cell lines could
possibly be used to develop noncarcinogenic human hepa-
tocytes. When incorporated into a BAL, this could result in
a functional device without the immunologic drawbacks and
the potential danger of a human hepatoblastoma cell line.
EXTRACORPOREAL WHOLE LIVER
PERFUSION
The need for hepatic tissue for effective treatment of
patients with ALF led to the concept of using the whole
liver in an extracorporeal perfusion system. Isolated liver
perfusion studies date back to the 19th century, when they
were performed to study liver metabolism, demonstrating
complex metabolic liver function outside the natural envi-
ronment of the liver.54 Not until 1958 was the first experi-
mental study carried out with allogeneic livers to clear
ammonia given to dogs. The study showed a significant
decrease in ammonia levels in animals treated by ex vivo
liver perfusion compared with control animals.55 The first
clinical study was performed in 1965 by Eiseman et al,56
who tested several perfusion circuits in pigs as well as
humans with ALF. During the past three decades, approx-
imately 141 ex vivo pig liver perfusions have been per-
formed to treat 87 patients with liver failure in usually poor
clinical condition (Table 3). The technique and clinical
outcome of extracorporeal whole pig liver perfusion, as
reported in well-documented studies comprising more than
one patient, are described below.
Experimental Setup
The pig liver has been used in most cases because it is
readily available. Immediately before perfusion, hepatec-
tomy is performed on pigs weighing 20 to 45 kg. In all
studies, the cystic duct is ligated, the common bile duct is
cannulated to collect the bile produced during perfusion,
and the hepatic artery and the portal vein are cannulated for
inflow of human blood. The inferior vena cava is either left
open, in which case outflow goes to a reservoir where the
patient’s blood is mixed with ascitic fluid and pumped back
into the circulation, or cannulated for immediate return of
blood to the patient. The isolated liver is placed in a sterile
Table 3. CLINICAL STUDIES USING
EXTRACORPOREAL PIG LIVER
PERFUSION
Investigators
Publication
Year
No. of
Patients
No. of
Perfusions
Eiseman* 1965/1966 8 11
Norman 1967 5 13
Watts* 1967 3 6
Bertrand 1968 10 15
Beveridge 1968 1 1
Mieny 1968 1 1
Ham 1968 1 2
Abouna* 1968/1969 4 7
Watts 1969 5 8
Schleifer 1969 2 2
Ha¨ring 1969 3 4
Chevrel 1969/1970 4 4
Abouna 1970 1 10
Ranek* 1971 5 7
Parbhoo* 1971 5 6
Lempinen 1971 1 3
Nielubowicz 1972/1973 5 10
Margulis 1975 10 10
Tung* 1981 9 13
Chari* 1994 4 8
Total: 87 141
* Studies analyzed for Table 4.
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perfusion chamber and connected to the patient’s circula-
tory system within no more than 30 minutes. Bile flow
proved to be the single most reliable index of hepatic
function and was assessed in all cases of extracorporeal
liver perfusion.
Many perfusion configurations have been tested.56 In
general, either blood is drawn from the femoral artery and
returned to the patient through the saphenous vein, or a
direct arteriovenous shunt in the upper arm is used.56–61 In
other studies, a venovenous shunt was used, placing a
double-lumen catheter in the femoral vein59 or using the
femoral and jugular veins.62 As is known from isolated liver
perfusion studies, oxygen supply to the liver is vital. There-
fore, the addition of a heater-oxygenator unit to the perfu-
sion system ensures a blood supply with a temperature of
37° to 39°C and 100% oxygen saturation. Thus, there is no
difference in performance of the ex vivo liver between
perfusing the hepatic artery and the portal vein or the portal
vein alone.56 A pump is used in the perfusion circuit, either
to return the blood from the reservoir containing “post”-ex
vivo liver blood to the patient56,58,60,61 or to create stable
and constant pressure and flow into the liver when a veno-
venous bypass was used.59,62 Length of extracorporeal pig
liver perfusion varied from 1.5 to 9 hours; one to four
perfusions were performed per patient. Regional or sys-
temic heparin was administered.
Clinical Outcome
For the literature review, references 56 to 62 were chosen
because their documentation is the best and the techniques
used for extracorporeal pig liver perfusion are comparable.
The variation in the cause of the hepatic failure among
individual patients from each study makes it hazardous to
compare the success rate of the ex vivo liver perfusion
technique. In addition, one is tempted to assume that some
groups of patients (e.g., those with ALF compared with
those with chronic liver disease) may exhibit a better out-
come; therefore, we determined neurologic improvement,
the percentage decrease in levels of NH3 or bilirubin before
and after perfusion, as well as the mean survival (in days) to
compare the results of patients with the same cause from the
different groups. Five patients who received eight perfu-
sions have been excluded because they had single-case
diseases such as hepatic failure from septic shock, hemo-
chromatosis, acetaminophen intoxication, and primary graft
nonfunction. Of the remaining 33 patients, 11 had cirrhosis
from alcohol abuse, 10 had viral hepatitis, and 12 had
hepatic failure not otherwise specified (Table 4). All pa-
tients had coma hepaticum grade IV to V (Table 5), and all
other treatments had failed to that point.
The results show neurologic improvement to at least
coma hepaticum grade III to II in most patients, which does
not seem to be related to the cause of the hepatic failure.
Moreover, no relation between clearance of NH3 or biliru-
bin and neurologic improvement or survival and cause was
demonstrated. This underlines the fact that the biochemical
parameters used to describe the function of the isolated liver
and to follow the clinical condition of patients with hepatic
failure do not reveal the mechanism of hepatic failure and
hepatic encephalopathy. Although controlled trials have not
yet been carried out, the complete recovery of three patients
and the prolonged survival of some patients strongly sug-
gest improvement over conventional treatment.
Most complications that accompany extracorporeal
Table 4. PATIENTS TREATED WITH EXTRACORPOREAL LIVER PERFUSION
Cause
No. of
Patients
No. of
Perfusions
Neurologic
Improvement/Perfusion
NH3
Decrease
(%)
Bilirubin
Decrease
(%) Survival (Mean)
Cirrhosis 11 15 14/15 55 36 4.8 days
Viral hepatitis 10 16 10/16 43 41 4.8 days 1 1 complete
recovery
Liver failure not
otherwise specified
12 19 16/19 25 47 4.3 days 1 2 complete
recoveries
Data from references 56–62.
Table 5. CLINICAL STAGES OF ACUTE
FULMINANT HEPATIC FAILURE
(HEPATIC COMA)
Grade Description Clinical Symptoms
I Neurasthenic
syndrome
Abnormal fatigability, depression,
confusion, altered mood or behavior,
appropriate response, slight tremor
II Somnolence Drowsiness, inappropriate behavior,
flapping tremor
III Sopor Reduced responsiveness, ability to obey
simple commands, incoherent speech,
Babinski
IV Coma No response to verbal stimuli, response
to painful stimuli, decerebrate, grossly
abnormal EEG
V Deep coma No response to pain, little or no EEG
activity
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whole liver perfusion are due to preexisting cardiopulmo-
nary disease, although hemodynamic changes during perfu-
sion were highly limited. Uncontrolled bleeding secondary
to thrombocytopenia as a result of the oxygenator in the
circuit or the development of disseminated intravascular
coagulation is another common complication. In three pa-
tients, a relapse to stage V hepatic encephalopathy eventu-
ally led to death.
Most ex vivo liver perfusion studies were performed in
the late 1960s and early 1970s; the method was then aban-
doned because of the successful development of orthotopic
liver transplantation (see Table 3). However, with the
present shortage of available donor organs, there is renewed
interest in this method.62–64 Although the results are en-
couraging, a controlled study has not yet been performed to
predict conclusively the outcome of extracorporeal whole
liver perfusion. Further, the immunologic implications of
human blood perfused through hepatic endothelial tissue are
unknown. This aspect will be considered in the next section.
IMMUNOLOGIC IMPLICATIONS
The use of extracorporeal pig liver perfusion or an artificial
liver device with pig hepatocytes implies contact of human
blood or plasma with porcine material. When such an xeno-
geneic contact is established, whether it be only once or several
times per patient for limited periods of time, immunologic
problems should be anticipated. In the first clinical study on
extracorporeal liver perfusion by Eiseman et al in 1965,56
C14-tagged glycine and lysine were added to the perfusion
system and synthesized into protein by the pig liver that prob-
ably contained the porcine amino acid code, suggesting ex-
change of biologic material between graft and host. Renewed
interest in the application of xenogeneic cells or tissues has
drawn attention to the possible immunologic consequences.
Although a cell-mediated reaction is seen at an early stage, as
indicated by activation of neutrophil granulocytes and natural
killer cells after suppression of complement,65,66 these mech-
anisms are probably less significant because therapy is in-
tended to last only several days. For this reason, we will focus
on the humoral response.
Humoral Response
Xenotransplantation normally leads to hyperacute rejec-
tion of the xenograft mediated by preformed naturally oc-
curring antibody (pNAb) and complement. These antibod-
ies, also called xenogeneic pNAbs, are directed against
porcine antigens and are present in most primates without
preceding sensitization. In humans, xenoreactive pNAbs,
which consist of IgG, IgA, and mainly IgM, form 2% to 4%
of the total immunoglobulins. Approximately 80% of these
pNAbs are directed against the GAL-alpha1,3 membrane
epitope, the most important target antigen of the human
humoral defense against porcine organs.66 pNAbs are
mainly produced by splenic B lymphocytes,67 and several
theories about their development have emerged. For in-
stance, they may be induced by contact between mucosal
immune cells and intestinal flora68 or food-derived antigens
with epitopes similar to GAL.69 Whether IgG, with a higher
affinity for pig antigens, or IgM, which is supposed to act as
an “early” antibody, plays the predominant role in comple-
ment activation and cytotoxicity has yet to be established.70
In a recent study by Schraa et al,71 rats were sensitized
against hamsters 1 and 5 weeks before hepatic xenografting;
high titers of IgM and IgG, respectively, were found. Hy-
peracute rejection was demonstrated in the second group but
not the first group, indicating the importance of IgG but not
IgM-mediated cytotoxicity in hepatic xenografting. As for
the direct effect of complement, both the classical and the
alternative pathways seem to be involved in the activation
and cytotoxicity of a xenogeneic reaction.69
Immunologic Aspects in Liver Perfusion
In patients with ALF, the levels of total CH50 and C3,
C4, C5 and the regulatory proteins factor I and beta-1H are
significantly lower compared with controls,72 whereas the
naturally occurring antibody levels do not differ. It is not
clear whether this complement depletion is the result of
impaired synthesis because of the diseased liver or ongoing
activation of the complement system, or a combination of
the two. Hyperacute rejection after xenogeneic kidney per-
fusion can be prevented only by complete inactivation of
complement,73 whereas the perfusion of a liver with human
blood is characterized by normal liver function for several
hours.74 At the same time, the drops in the levels of pNAbs
during kidney and liver perfusion are similar. However,
immunohistochemical analysis of the kidneys after perfu-
sion with human blood demonstrates the binding of both
IgM and IgG xenoantibodies and complement (C3) to kid-
ney vascular endothelium, whereas staining was minimal
for liver vascular endothelium.75
Tector et al76 confirmed these data in an isolated liver
perfusion study of blood from patients with liver failure.
They showed significantly reduced complement levels and
activity compared with normal subjects, resulting in an
impaired ability to lyse both aortic and sinusoidal endothe-
lial cells. Immunofluorescent analysis showed little or no
staining for sinusoidal deposition of IgM, IgG, or C3, sug-
gesting that the sinusoidal endothelium of the liver can
remove antibody and complement without cell lysis, possi-
bly by endocytosis, compared with aortic or other endothe-
lium.
The same results were obtained in a clinical study in
which no adverse effects on ex vivo organ function were
measured during treatment of patients with ALF by extra-
corporeal pig liver perfusion. Again, low complement lev-
els, normal amounts of pNAb, and, after perfusion, only
trace deposits of pNAb and C3 on the sinusoidal endothe-
lium with a decrease in the level of pNAb were demonstrat-
ed.77 Long-term follow-up of these patients showed an
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increase in xenoreactive IgM and IgG within 10 days of
perfusion and a subsequent return to normal.78 These con-
cepts are being used to study ways to delay hyperacute
rejection (Table 6).79 Several strategies are being tested in
different organs, with encouraging results. The efficacy of
humoral mediators present in serum has been reduced by
means of porcine livers transgenic for human decay-accel-
erating factor (DAF/CD55).80 Reduced humoral injury was
found with soluble complement receptor type 1,81 and im-
munopheresis was successfully used to remove xenogeneic
pNAb before perfusion of the liver, which resulted in im-
proved functioning of the perfused liver.82
The role of the immunologic defense in the treatment of
patients with liver failure is far from clear, but no immu-
nologic adverse reactions have been detected during treat-
ment in the clinical studies reported thus far. In one patient
with chronic aggressive hepatitis who underwent 16 extra-
corporeal liver perfusions in 2.5 months, a decrease in
antibodies could be shown after every perfusion. This was
followed by a progressive rise in the titer of these antibod-
ies, which peaked during the fifth perfusion, when an ana-
phylactic reaction was recorded; the next five perfusions
with a pig liver did not cause detrimental effects.83 Whether
prolonged or repetitive treatment leads to sensitization of
the patient to porcine antigens remains to be determined.
Immunologic Aspects of Artificial Liver
Devices
Unlike extracorporeal whole liver perfusion, where hu-
man blood is in direct contact with porcine liver endothe-
lium, artificial liver systems contain only pig hepatocytes
and are usually perfused with human plasma, because a
plasma separation unit is used in the perfusion circuit. As
described before, the hollow fiber bioreactor consists of
several compartments that communicate through the pores
in the fiber walls, allowing mass transfer between the pa-
tient’s plasma and the heterologous hepatocytes. The size of
the pores is determined by the balance between sufficient
waste removal and potential immune activation. Removal of
ammonia, aromatic amino acids, and red blood cell break-
down products such as bilirubin (0.6 kDa) is desirable.
Coagulation proteins such as prothrombin (70 kDa) and
thrombin (40 kDa) could potentially benefit the patient,
which is why they should be allowed to pass through the
fiber membrane. However, immunoglobulins (150–900
kDa) and cytokines (100–400 kDa) preferably do not make
contact with the hepatocytes. The ideal molecular weight
cutoff therefore may lie between 50 and 100 kDa,35 which
should theoretically prevent a cellular as well as a humoral
immune response.
However, te Velde et al84 showed that rats infused with the
supernatant of in vitro cultured pig hepatocytes raised antibod-
ies against the very small amounts of pig hepatocyte-derived
proteins in the culture medium. Another study showed an
increase in tumor necrosis factor-alpha after a 4-day perfusion
of pigs connected to a hybrid liver support system containing
homologous hepatocytes,85 although no typical side effects
were observed. In a clinical study of patients with ALF treated
with the BAL, antipig xenoantibodies (IgM and IgG) remained
at the same level 10 days after treatment, when one treatment
was carried out. If more than one treatment was given, the
levels increased two- to threefold and decreased only if immu-
nosuppression was administered because of subsequent liver
transplantation.86 Thus, either through contact of human
plasma with the pig hepatocytes during perfusion or because of
pig hepatocyte material entering the human circulation, an
immunologic reaction can be induced. Whether this is clini-
cally relevant remains to be seen, because so far no side effects
have been noticed.
Cellular and humoral graft-versus-host reactions also
must be considered, although thus far there is no proof of
this type of reaction in the literature. In a baboon-to-human
liver transplantation, no baboon antibodies were detected in
the human serum.87 Another problem is the potential risk of
zoonosis. Patience et al88 showed that porcine kidney cell
lines release particles of pig endogenous retrovirus, which
can infect human cell lines in vitro. However, transmission
of pig endogenous retrovirus from transplanted porcine
endothelial cells to baboons89 or humans90 in vivo has not
been detected. Obviously, these issues need further attention
if artificial liver systems are to be used in clinical trials.
CONCLUSIONS
Two major concerns are noted in the literature on extra-
corporeal liver perfusion for the treatment of liver failure.
Table 6. STRATEGIES TO OVERCOME
HYPERACUTE REJECTION OF PIG-TO-
HUMAN XENOGRAFTS
Antibody
• Removal by plasmapheresis, immunopheresis
• Removal by absorption with pig organs
• Removal by absorption on gal columns
• Block with high avidity chicken anti-GAL
• Block with peptides
Antigen
• Gene knockout (not in pig)
• Antisense constructs
• Enzymatic destruction:
External
Galactosidase transgene
• Suppress GAL:
H transferase transgene
• Secretor gene
Complement
• Cobra venom factor
• Antibodies
• Soluble complement receptor type 1
• Transgenes (CD46[MCP], CD55[DAF], CD59)
Adapted from McKenzie et al.79
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First, there is still no clear understanding of the biologic
mechanisms of liver failure; therefore, the various ap-
proaches to temporary treatment of this disease lack a
well-defined basis. Second, no uniform definition of liver
failure is given. Within studies and between studies, there is
a wide variety in the severity of liver disease, and success of
treatment is defined in many ways. Although most studies
report temporary improvement of the patient’s clinical neu-
rologic condition, evidence-based research indicating suc-
cessful treatment has not yet been reported. Therefore, in
our opinion, randomized studies that focus on a well-de-
fined method and include sufficient patients to allow ade-
quate statistical analysis are needed to determine the effi-
cacy of this approach. Only then can conclusive evidence be
gathered to benefit patients with liver failure who undergo
either extracorporeal whole liver perfusion or treatment
with a BAL.
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